SAM
AVIR icon

Smartleaf Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Smartleaf Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Hold
3,325
– – ﹤0.01% 2156
2026
Q1 		$16.9K Buy
3,325
+25
+0.8% +$115 ﹤0.01% 2047
2025
Q4 		$11.7K Buy
+3,300
New +$10.5K ﹤0.01% 2323
2024
Q3 		– Sell
-46
Closed -$155 – 2910
2024
Q2 		$155 Buy
+46
New +$172 ﹤0.01% 2701

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smartleaf Asset Management's AVIR Position: Q2 2026 in Review

Smartleaf Asset Management held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 3,325 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

Smartleaf Asset Management first reported a position in AVIR in Q2 2024 and has held it in 4 quarters since. The position peaked at $16.9K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Smartleaf Asset Management held 3,325 shares of Atea Pharmaceuticals worth $15.3K as of Q2 2026.
  • Smartleaf Asset Management left its Atea Pharmaceuticals share count unchanged in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2156 holding.
  • Smartleaf Asset Management first reported a position in Atea Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Smartleaf Asset Management's Atea Pharmaceuticals position peaked at $16.9K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.